- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03226613
New Modalities for Detection of Oropharyngeal Cancer
Advancing New Modalities for the Detection of Oropharyngeal Cancer: Transcervical Ultrasound and HPV16 E6 Antibodies
Background: The incidence of human papilloma virus-driven oropharyngeal cancer (HPV-OPC), a type of head and neck cancer, is rapidly increasing within the US. Currently, there are no screening methods for early detection. HPV16 E6 antibodies combined with ultrasound imaging may be a promising method for early detection of HPV-OPC. However, prior to testing HPV16 E6 antibodies and ultrasound for HPV-OPC screening, larger studies are needed to further validate the utility of these methods in the diagnostic setting among patients with suspected and/or symptomatic HPV-OPC.
Objective/Hypothesis: To investigate two promising screening modalities for the detection of HPV-OPC, transcervical ultrasound and HPV16 E6 antibodies. The investigators hypothesize that both ultrasound and HPV16 E6 antibodies will be highly sensitive for the detection of symptomatic HPV-OPC.
Specific Aims: (1) Determine the sensitivity of ultrasound to characterize OPC tumors compared to current standard imaging modalities among patients with suspected or confirmed OPC. (2) To determine the sensitivity and specificity of HPV16 E6 antibodies for HPV-OPC. (3) Determine the sensitivity of ultrasound to detect HPV-OPC compared to current standard imaging modalities among patients that present with a neck mass and unknown primary tumor.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37220
- Vanderbilt University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 21 years or older
- Suspected or confirmed oropharyngeal cancer
- Previously untreated cancer
- First cancer diagnosis
Exclusion Criteria:
- No to any of the inclusion criteria
- Under 21 years of age
- Inability to provide blood or oral rinse specimen
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Patients with suspected or known oropharyngeal cancer
Patients with either known or suspected oropharyngeal cancer will be asked to undergo a transcervical ultrasound and to provide a blood and oral rinse specimen.
|
One time approximately 15 minute ultrasound will be conducted at the time of clinic visit, focusing on the base of tongue and palatine tonsil via transcervical approach.
Other Names:
Patients will provide a one time oral rinse specimen using a non-alcoholic mouthwash at the time of clinic visit.
The participant will be instructed to swish vigorously for 5 seconds and then gargle 5 seconds.
The participant will be asked to repeated the swish and gargle (5 seconds each) three times for a total of 30 seconds and then expel the wash in a 10mL conical tube.
A certified phlebotomist will perform a one time blood draw of 10mL at the time of clinic visit from each participant for purposes of HPV serologic testing.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Detection of tumor via transcervical ultrasound
Time Frame: 1 day at time of clinic visit
|
Ability to detect oropharyngeal tumor via ultrasound will be a primary outcome of the study.
Characteristics including ability to detect tumor, tumor size, and tumor location will be recorded at time of ultrasound.
The ultrasound findings will then be compared to other imaging modalities used as standard work-up (CT/MRI).
This comparison will be used to determine sensitivity of ultrasound for detection of oropharyngeal tumors.
|
1 day at time of clinic visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HPV Serology
Time Frame: Through study completion, an average of 1 year
|
Both serum samples and oral rinse specimens will be shipped to German Cancer Research Center, Heidelberg (DKFZ) for blinded analysis of HPV antibodies.
The samples will be completely de-identified prior to shipment and thus, there will be no way for the testing laboratory to link the specimens back to the patients.
A random sample of blinded duplicates (10%) will be included as part of quality control.
Seroreactivity against the HPV16 E6 protein will be determined using multiplex serology, an antibody detection method based on a glutathione S-transferase capture ELISA in combination with fluorescent bead technology.
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Krystle A Kuhs, PhD, Assistant Professor for Division of Epidemiology and Department of Otolaryngology, Vanderbilt University Medical Center
Publications and helpful links
General Publications
- Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011 Nov 10;29(32):4294-301. doi: 10.1200/JCO.2011.36.4596. Epub 2011 Oct 3.
- Coquia SF, Hamper UM, Holman ME, DeJong MR, Subramaniam RM, Aygun N, Fakhry C. Visualization of the Oropharynx With Transcervical Ultrasound. AJR Am J Roentgenol. 2015 Dec;205(6):1288-94. doi: 10.2214/AJR.15.14299.
- Fakhry C, Agrawal N, Califano J, Messing B, Liu J, Saunders J, Ha P, Coquia S, Hamper U, Gillison M, Blanco R. The use of ultrasound in the search for the primary site of unknown primary head and neck squamous cell cancers. Oral Oncol. 2014 Jul;50(7):640-5. doi: 10.1016/j.oraloncology.2014.03.015. Epub 2014 May 10.
- Kreimer AR, Johansson M, Yanik EL, Katki HA, Check DP, Lang Kuhs KA, Willhauck-Fleckenstein M, Holzinger D, Hildesheim A, Pfeiffer R, Williams C, Freedman ND, Huang WY, Purdue MP, Michel A, Pawlita M, Brennan P, Waterboer T. Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer. J Natl Cancer Inst. 2017 Aug 1;109(8):djx005. doi: 10.1093/jnci/djx005.
- Holzinger D, Wichmann G, Baboci L, Michel A, Hofler D, Wiesenfarth M, Schroeder L, Boscolo-Rizzo P, Herold-Mende C, Dyckhoff G, Boehm A, Del Mistro A, Bosch FX, Dietz A, Pawlita M, Waterboer T. Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16-driven oropharyngeal squamous cell carcinoma. Int J Cancer. 2017 Jun 15;140(12):2748-2757. doi: 10.1002/ijc.30697. Epub 2017 Apr 4.
- Lang Kuhs KA, Pawlita M, Gibson SP, Schmitt NC, Trivedi S, Argiris A, Kreimer AR, Ferris RL, Waterboer T. Characterization of human papillomavirus antibodies in individuals with head and neck cancer. Cancer Epidemiol. 2016 Jun;42:46-52. doi: 10.1016/j.canep.2016.03.003. Epub 2016 Mar 21.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Carcinoma, Squamous Cell
- Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Oropharyngeal Neoplasms
- Tonsillar Neoplasms
Other Study ID Numbers
- 170297
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oropharynx Cancer
-
Brooke Army Medical CenterCompleted
-
Emory UniversityNational Cancer Institute (NCI); Genentech, Inc.RecruitingOropharynx Cancer, Stage IUnited States
-
Loren Mell, MDMerck Sharp & Dohme LLCRecruitingCancer | Head and Neck Squamous Cell Carcinoma | Oral Cancer | Tumor | Oropharynx Cancer | Cancer of Head and Neck | Oropharyngeal Cancer | Cancer, Advanced | Cancer, Metastatic | Tumor Metastasis | Tumor Recurrence | Tumor Neck | Oropharynx Cancer, Stage III | Oropharynx Cancer, Recurrent | Oropharynx Cancer, MetastaticUnited States
-
Memorial Sloan Kettering Cancer CenterWithdrawn
-
Duke UniversityRecruitingOropharynx CancerUnited States
-
Icahn School of Medicine at Mount SinaiActive, not recruitingLocally Advanced HPV Positive Oropharynx CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterCompletedHead and Neck Cancer | Oropharynx Cancer | Xerostomia Due to RadiotherapyUnited States
-
University Hospital, Basel, SwitzerlandRecruitingOral Cavity Defect | Oropharynx DefectSwitzerland
-
University of ChicagoNational Cancer Institute (NCI)TerminatedTongue Cancer | Stage I Squamous Cell Carcinoma of the Oropharynx | Stage II Squamous Cell Carcinoma of the Oropharynx | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IVA Squamous Cell Carcinoma of the OropharynxUnited States
-
Region Örebro CountyVärmland County Council, Sweden; Region Stockholm; Dalarna County Council, Sweden and other collaboratorsActive, not recruitingOropharynx Cancer | Oropharynx Squamous Cell Carcinoma | Base of the Tongue Carcinoma | Tonsillar CancerSweden
Clinical Trials on Transcervical Oropharyngeal Ultrasound
-
Rigshospitalet, DenmarkThe Novo Nordic FoundationCompletedOropharynx Cancer | Tonsil Cancer | Tonsil Hypertrophy | Tonsil Neoplasm | Tonsil Lymphoma | Base of Tongue Carcinoma | Oropharynx Neoplasm | Base of Tongue TumorDenmark
-
University of Alabama at BirminghamCompletedCervical Ripening | Labor InductionUnited States
-
Rigshospitalet, DenmarkThe Novo Nordic FoundationRecruitingOropharynx Cancer | Tonsil Cancer | Tonsil Hypertrophy | Base of the Tongue Tumor | Tonsil Ulcer | Tonsil Neoplasm | Tonsil Lymphoma | Base of Tongue CarcinomaDenmark
-
Assaf-Harofeh Medical CenterNot yet recruitingFallopian Obstruction Tube
-
Shenzhen People's HospitalShenzhen Bao'an Maternal and Child Health Hospital; Longgang Maternal and Child...Not yet recruitingGut Microbiota | MetabolitesChina
-
University of Alabama at BirminghamTerminatedFetal Membranes, Premature Rupture | Labor, Induced/ISUnited States
-
Hadassah Medical OrganizationUnknown
-
Seoul National University HospitalCompletedPremature Infant | Extremely Low Gestational Age NewbornKorea, Republic of
-
Hologic, Inc.QST Consultations, Ltd.TerminatedReproductive SterilizationUnited States, Australia, Mexico
-
University of California, San FranciscoTerminatedLabor, Induced | Cervical RipeningUnited States